TNFs & TNFRs: Popular Targets in Immunotherapy

Tumor necrosis factors (TNFs) and their corresponding receptors (TNFRs) play crucial roles in regulating the immune system. Dysregulation of TNFs/TNFRs is closely linked to tumorigenesis, progression, invasion, and metastasis. Thus, there has been an upsurge of interest in targeting TNFs/TNFRs for cancer immunotherapy in recent years.

The FDA has approved five medicines that target BCMA for myeloma as of January 2024. An antibody-drug conjugate (ADC) targeting CD30, Brentuximab vedotin, has also been approved by the FDA to specifically target mesenchymal large-cell lymphoma and Hodgkin’s lymphoma.

TNFs also frequently target TNFRs such as 4-1BB, Fas/CD95, and GITR, while other targets include RANKL, TRAIL, BLys, and CD40L. Drugs that target these TNFs/TNFRs are either authorized for clinical use already or are undergoing clinical trials.

Sino Biological offers a comprehensive selection of recombinant TNF and TNFR proteins and corresponding antibodies that support drug discovery and development research on TNFs/TNFRs.

TNF receptor superfamily targeted therapy in cancer

TNFRSF molecules and ligands are targeted on cells of the immune system to boost immune activity against a tumor cell or on tumor cells to either directly promote apoptotic cell death or focus cytotoxic mechanisms toward a tumor cell.